stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence an analysis of 42 cases立体定向放射治疗对转移性肺癌oligo-recurrence分析42例.pdfVIP

Hindawi Publishing Corporation Pulmonary Medicine Volume 2012, Article ID 454107, 5 pages doi:10.1155/2012/454107 Clinical Study Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases Wataru Takahashi,1 Hideomi Yamashita,1 Yuzuru Niibe,2 Kenshiro Shiraishi,1 Kazushige Hayakawa,2 and Keiichi Nakagawa1 1 Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan 2 Department of Radiology and Radiation Oncology, Kitasato Universtiy, Kanagawa 252-0374, Japan Correspondence should be addressed to Hideomi Yamashita, yamachayahoo.co.jp Received 11 June 2012; Revised 3 August 2012; Accepted 3 September 2012 Academic Editor: Takao Hiraki Copyright © 2012 Wataru Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1–90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75–99%) and 65% (95% CI, 48–82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) 31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI